- ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
- ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- ImmunoGen Appoints Michael Vasconcelles, MD, as Executive Vice President, Research, Development, and Medical Affairs
- ImmunoGen Announces Susan Altschuller on FMLA Leave; Interim CFO Appointed
- ImmunoGen Announces Webcast of Presentation and Q&A at the 41st Annual J.P. Morgan Healthcare Conference
- ImmunoGen Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH
- ImmunoGen Announces Clinical Collaboration with Gilead to Evaluate Pivekimab Sunirine in Combination with Magrolimab in Relapsed/Refractory Acute Myeloid Leukemia
- ImmunoGen Appoints Daniel Char as Senior Vice President and Chief Legal Officer
- ImmunoGen Announces FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer
More ▼
Key statistics
On Friday, ImmunoGen Inc (IMGN:NSQ) closed at 4.66, 50.57% above the 52 week low of 3.10 set on Jun 14, 2022.
52-week range
Markit short selling activity
Open | 4.80 |
---|---|
High | 4.90 |
Low | 4.63 |
Bid | 4.62 |
Offer | 4.90 |
Previous close | 4.66 |
Average volume | 2.78m |
---|---|
Shares outstanding | 220.75m |
Free float | 219.84m |
P/E (TTM) | -- |
Market cap | 1.03bn USD |
EPS (TTM) | -0.8151 USD |
Data delayed at least 15 minutes, as of Feb 03 2023 21:00 GMT.
More ▼